Market Overview:

The Global Drug Delivery Devices Market size was valued at USD 284.49 billion in 2023 and it is predicted to hit USD 437.57 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 4.90% during the forecast period 2024 to 2032. In 2022, North America market has held highest revenue share of over 38%.

The industry is anticipated to grow overall because to the increasing usage of cutting-edge technology to efficiently deliver medications to the proper place. The adoption of these drug delivery devices also reduces the risk of unfavourable outcomes by improving medication administration at the intended area. This reduces the dosage and any negative effects that may be related. Because there are less active pharmaceutical chemicals used, this also contributes to a lower overall product price. R&D in the field is anticipated to increase in response to the growing need for innovative medication delivery devices.

Major players in the market are always creating strategic alliances to develop cutting edge technology for a variety of applications.

Specifically for drug delivery and pharmaceutical contact applications, Victrex plc, a company well-known for its cutting-edge PEEK biomaterial solutions, developed the VICTREX PC101 grade in October 2023. In keeping with the growing trend of deploying drug delivery systems in home-care settings, the launch of this product will increase patient access to these cutting-edge technologies.

Different companies are creating patient-friendly drug delivery systems in response to the growing demand, and other market participants are purchasing these businesses to broaden their portfolio. By purchasing Aveva Drug Deliver Services Inc. in April 2023, DifGen Pharmaceuticals bolstered its position as a provider of complex medication dosage forms. By strategically locating itself in the US, DifGen is able to increase its development and manufacturing capabilities while simultaneously strengthening its capabilities.

Medical professionals are always researching how to improve the accuracy, patient-friendliness, and accessibility of drug delivery devices using technology. Aggressive drug delivery devices and cutting-edge technology are always being researched by industry participants. One company working to improve the safety and effectiveness of medication delivery systems is AstraZeneca, which is creating next-generation technology. By creating medicines that are more convenient, easier to use, and require fewer dosages than previously, they are focusing on enhancing the patient experience. Furthermore, recent technologies are always being developed and applied by the pharmaceutical businesses to further the design and development of contemporary drug-providing systems. The development of novel drug concepts like target-based drug discovery and the visualisation of drug interactions at the molecular level have been facilitated by computational research. The industry wants to enhance the way that patients experience medications by furthering the science of drug administration.

It is anticipated that some obstacles may hinder the growth of the market despite the benefits and innovations linked to these medication delivery systems. Its inefficiency in delivering drugs that are poorly soluble poses the biggest problem for these drug delivery devices. It is also anticipated that further obstacles to the bioavailability of poorly soluble tablets may hinder the market's expansion. Furthermore, uncontrollably released medications on the infection site by these pharmacological devices may result in additional side effects like allergies and infections.

Market Dynamics:

Market Drivers:

Rising Prevalence of Diseases

• The increasing occurrence of both acute and chronic illnesses and infections worldwide is a primary driver of the market value rise. More than 20 million people in the nation currently have diabetes, and by 2025, that number is expected to rise to almost 57 million, according to a recent estimate. Within the previously stated estimated timeframe, this will further propel the market and result in the expansion of the drug delivery devices market.

Research and Development Proficiencies

• Increased investment in R&D capabilities, particularly in developed and developing nations, with respect to medical devices and instruments, will further open up profitable growth prospects for the industry. Additionally supporting the market growth rate is the research and development expertise being used to live viruses in order to create medications.

Market Trends:

Topical Drug Delivery Devices Segment is Estimated to Witness a Healthy Growth Over the Forecast Period

• Drugs are transported by a topical product to a local target site on the skin, where they are subsequently cleared via diffusion, metabolism, and dermal circulation to reach deeper tissues and the rest of the body.
• Two main drivers of the segment's growth are the creation of new products and the growing execution of strategic projects. Scientists at Stanford University and the University of North Carolina at Chapel Hill (UNC), for example, created a 3D-printed vaccine patch in March 2021 that they assert offers better protection than a standard vaccination shot. The creation of these innovative goods is encouraging the use of drug delivery devices, which is fostering market expansion.
• Additionally, there are a number of cancer-related applications for topical medication delivery, which is anticipated to accelerate market expansion. For example, a Frontiers article from October 2022 states that topical drug delivery via the skin can be used to deliver drugs locally in skin cancer cases because it has several advantages over oral administration, including avoiding issues with pH, stomach emptying, enzyme deactivation, and first-pass metabolism.
• Numerous industry participants are actively executing strategic initiatives, which in turn facilitates market expansion. For example, the Twirla (levonorgestrel and ethinyl estradiol) transdermal device, a novel non-daily, non-invasive contraceptive patch, was commercially introduced by women's healthcare business Agile Therapeutics, Inc. in December 2020. Additionally, Vektor Pharma released a generic version of the Neupro patch (rotigotine), a transdermal patch that indicated against Parkinson's disease symptoms, in June 2020.

Connected Devices and Telemedicine

• Sensors and networking capabilities allow smart drug delivery systems to capture data in real time, which is useful for tracking physiological data and learning about medication adherence and consumption trends. By empowering patients and facilitating prompt action by healthcare professionals, this connectivity enables better tracking of drug adherence through reminders and refill alerts. Furthermore, by providing virtual consultations for medication changes and problem solving, telemedicine platforms enable improved contact between patients and doctors. Combining telemedicine with connected devices creates a synergistic effect that optimises resource allocation, improves treatment outcomes, and eases the strain on patients.

Market Restraining Factors:

High Cost Associated with the Research and Development Proficiencies

• High-tech medical device development requires significant investments in clinical studies, technology, and regulatory approvals; these costs are reflected in the devices' final costs. Likewise, the production expenses of advanced features-rich devices are frequently greater, which can restrict their availability in areas where healthcare funding is limited. Patients in low-resource situations who would find it difficult to afford such devices are impacted, leading to unequal access to therapy. Not only that, but this exorbitant price may limit market penetration and growth prospects for novel medical technology. The industry is looking into ways to improve accessibility and affordability for patients globally, including streamlining R&D procedures, developing affordable substitutes, and putting government support programmes into place.

Key Industry Developments:

In July 2021, Johnson & Johnson received FDA approval for DARZALEX (daratumumab), a subcutaneous formulation that reduces the treatment time for multiple myeloma indications.

In December 2020, Pfizer, Inc. received FDA approval for BRAFTOVI (encorafenib) plus combination with cetuximab for the treatment of patients with brafv600e-mutant metastatic colorectal cancer (CRC) who have undergone prior therapy.

In November 2020, GlaxoSmithKline plc partnered with IDEAYA to enter the field of Synthetic Lethality, an emerging field in oncology; programs MAT2A, Pol Theta, and Werner Helicase programs, which are part of it, are projected to reach clinical trials in the next three years.

Report Coverage:

The report will cover the qualitative and quantitative data on the global Drug Delivery Devices Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

By Route of Administration (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical, Others), By Application (Oncology, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Others), By End-use (Hospitals, Diagnostic Centres, Ambulatory Surgery Centres/Clinics, Home Care Settings, Others)

Report Scope and Segmentations:

Drug Delivery Devices Market Players Analysis:

• Pfizer, Inc.
• Johnson & Johnson Services, Inc.
• Hoffmann-La Roche, Ltd.
• Novartis AG
• Bayer AG
• uniQure N.V.
• Sibiono GeneTech Co. Ltd
• Novartis AG
• Becton, Dickinson and Company
• Altaris
• Holozymes Inc. (Antares Pharma Inc.)
• GlaxoSmithKline PLC
• Teva Pharmaceutical Industries Ltd
• Biocorp
• Merck KGaA
• West Pharmaceutical Services Inc.
• Molex (Philips Medisize)
• Elcam Medical

Drug Delivery Devices Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2024-2032 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.

Drug Delivery Devices Market Segmentation Analysis:

By Route of Administration

• Oral
• Inhalation
• Transdermal
• Injectable
• Ocular
• Nasal
• Topical
• Others

By Application

• Oncology
• Infectious Diseases
• Respiratory Diseases
• Diabetes
• Cardiovascular Diseases
• Autoimmune Diseases
• Central Nervous System Disorders
• Others

By End-use

• Hospitals
• Diagnostic Centres
• Ambulatory Surgery Centres/Clinics
• Home Care Settings
• Others

Segmentation Analysis:

The market scope is segmented because of By Route of Administration, By Application, By End-use.

By Route of Administration

Based on the Route of Administration of the market is segmented into Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical, Others.

The oral, inhalation, transdermal, injectable, ocular, nasal, topical, and other sectors of the market are divided according on the methodology of administration. Administration routes including subcutaneous, intradermal, and intravenous are covered in the others section. By having a market share of 26.81% in 2023, the oral method of administration segment is leading the market.

Tablets, capsules, syrups, solutions, and suspensions are just a few of the many dosage forms available in the oral drug delivery system. Tablets and films that are distributed are also included in this category. Regarding cost, stability, ease of usage, and safety, the oral route is the recommended method of administration. For respiratory disorders like asthma and chronic obstructive pulmonary disease (COPD), inhalation medication delivery systems are the recommended method of administration. It is anticipated that this market would expand due to factors including the rising incidence of respiratory illnesses and the development of inhalation devices like nebulizers and inhalers.

During the projection period, the injectable route of administration is anticipated to grow at the quickest CAGR. Prefilled syringes and pen injectors are two examples of advances in injectable drug delivery methods that have raised demand in recent years. Moreover, the market is expanding because to the development of syringe materials such polymers, which are inert to the majority of chemicals.

By Application

Based on the Application of the market is segmented into Oncology, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Others.

Application-wise, the market is divided into categories such as neurology, diabetes, cardiovascular diseases, infectious diseases, respiratory disorders, cancer, and others. Ocular and endocrine problems are included in the others section. With a market share of 21.12% in 2023, diabetes drug delivery devices dominated the industry. Primarily, this is because diabetes is becoming more common. The CDC estimates that in 2022, 37.3 million Americans—or 11.3% of the total population—will be impacted, indicating a substantial impact. Twenty-seven million of them—or 28.5 million adults—have been diagnosed. An additional 8.5 million people—or 23.0% of adult undiagnosed cases—have not been diagnosed.

The market was dominated by the oncology segment, which is expected to expand at a modest pace of growth over the next several years due to the rising incidence of cancer worldwide. US doctors identified 1,918,030 new cases of cancer in 2022. Albumin nanoparticle and liposomal drug delivery systems are the two main types of drug delivery systems employed in oncology.

For the course of the forecast period, the Central Nervous System (CNS) diseases sector is expected to rise at a CAGR of 6.65%. Over the projection period, rising rates of neurological conditions such Parkinson's disease, Alzheimer's disease, Hunter's syndrome, and brain tumours are anticipated to fuel the segment's expansion. New CNS devices are therefore being created based on rational drug design to improve the treatment of these neurological illnesses, and these devices use receptor-ligand interaction to understand the appropriateness of medication delivery at the site.

By End-use

Based on the End-use of the market is segmented into Hospitals, Diagnostic Centres, Ambulatory Surgery Centres/Clinics, Home Care Settings, Others

The market is split into groups based on applications, including cancer, infectious diseases, heart disease, neurological conditions, diabetes, and respiratory issues. Under "others," you will find disorders related to the eyes and the hormones. Diabetes medication delivery devices dominated the market in 2023, accounting for 21.12% of the total. This is mostly due to the rising prevalence of diabetes. According to CDC estimates, the impact will be significant, affecting 37.3 million Americans in 2022, or 11.3% of the total population. Of them, 27 million have been diagnosed, or 28.5 million people. 23.0% of adult undiagnosed cases, or an extra 8.5 million people, are still undiagnosed.

The oncology category, which held a dominant position in the market, is anticipated to rise at a moderate rate over the next years due to the rising incidence of cancer globally. 1,918,030 new cases of cancer were diagnosed by US physicians in 2022. In cancer, liposomal and albumin nanoparticle drug delivery methods are the two primary varieties used.

Over the course of the projected period, a compound annual growth rate (CAGR) of 6.65% is anticipated for the Central Nervous System (CNS) illnesses industry. The segment is expected to grow during the projection period because to an increase in the prevalence of neurological disorders like brain tumours, Parkinson's disease, Alzheimer's disease, and Hunter's syndrome. Consequently, new CNS devices that utilise receptor-ligand interaction to determine the appropriateness of medication delivery at the location are being developed based on rational drug

Regional Snapshots:

North America accounted for the highest market share in 2023, with a share of 32.39%. Drug supply devices are becoming more and more popular, which is explained by the presence of big players in the area. Further projected to support market expansion in the region is growing awareness of the benefits of medication delivery devices throughout the region. Further anticipated to support market expansion is the rising product approval rates in nations like the United States. Vertiva, an adaptable medication distribution platform ideal for a broad range of medicines and high approach volumes, was introduced by Stevanato Group in June 2023.

The Europe area is predicted to expand at a modest CAGR and held a sizable proportion in 2023. For the main market participants in the area, developed economies and advantageous regulatory frameworks are among the main elements offering enormous prospects. Due to the high pace of economic growth in the region, Asia Pacific is anticipated to increase at the highest rate during the projection period. Adoption of drug supply devices by different end-users is also being facilitated by a sizable patient pool in nations like China, India, and Japan. Furthermore, many kinds of medication delivery equipment are used in Japan to deliver particular kinds of medications.

Drug Delivery Devices Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S.
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report:

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions:

• How much the global Drug Delivery Devices Market valued?
• Which region has the largest share in 2024 for the global Drug Delivery Devices Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Drug Delivery Devices Market:

• Historic year: 2018- 2022
• Base year: 2022
• Forecast: 2023 to 2031
• Representation of Market revenue in USD Million

Drug Delivery Devices Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: